Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) is anticipated to announce its earnings results before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of ($1.31) per share and revenue of $117.02 million for the quarter.
Ascendis Pharma A/S Stock Performance
NASDAQ ASND traded down $1.82 on Wednesday, reaching $127.55. The company's stock had a trading volume of 192,663 shares, compared to its average volume of 459,717. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $161.00. The firm's 50 day moving average is $133.53 and its two-hundred day moving average is $133.03. The stock has a market cap of $7.74 billion, a PE ratio of -15.79 and a beta of 0.65.
Analyst Ratings Changes
Several brokerages have recently commented on ASND. StockNews.com upgraded shares of Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th. Cantor Fitzgerald restated an "overweight" rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. UBS Group initiated coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price objective on the stock. TD Cowen cut their price target on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating for the company in a report on Friday, November 15th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an "overweight" rating in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $191.57.
Read Our Latest Stock Report on ASND
About Ascendis Pharma A/S
(
Get Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
See Also
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
